Q2 FY2026 · ended Jun 30, 2026 · Revenue $287,000, -9.2% YoY · Filed Aug 12, 2026
Longeveron Inc. (LGVN) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $287,000 and a net loss of $6.1 million. Free cash flow was -$5.8 million. As of Jun 30, 2026 it held $18.1 million in cash and investments and $581,000 in total debt.
Revenue
$287,000
-9.2% vs year-ago quarter
Net income
$-6.07M
-20.8% vs year-ago quarter
Operating cash flow
$-5.65M
-57.2% vs year-ago quarter
Free cash flow
$-5.76M
-53.2% vs year-ago quarter
EPS
$-0.19
+42.4% vs year-ago quarter
Dividend per share
None
Shares outstanding
—
Net cash
$17.52M
Q2 FY2026
Operating margin
-1992.8%
TTM
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- LGVN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Miami, FL
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1721484
- Former names
- LONGEVERON LLC (until Feb 10, 2021)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
Q2 FY2025 Jun 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $287,000 | $398,000 | $365,000 | $137,000 | $316,000 |
| Operating income | -$6.2M | -$4.8M | -$5.4M | -$7.3M | -$5.4M |
| Net income | -$6.1M | -$4.7M | -$5.4M | -$7.2M | -$5.0M |
| Diluted EPS | -$0.19 | -$0.19 | -$0.00 | -$0.39 | -$0.33 |
| Operating cash flow | -$5.7M | -$4.4M | -$5.3M | -$5.1M | -$3.6M |
| Free cash flow | -$5.8M | -$4.4M | -$5.3M | -$5.1M | -$3.8M |
| Total assets | $15.5M | $21.2M | $10.3M | $15.6M | $16.7M |
| Total liabilities | $5.1M | $5.2M | $4.6M | $5.6M | $4.1M |
| Stockholders' equity | $10.4M | $16.0M | $5.7M | $10.0M | $12.7M |
| Cash and investments | $18.1M | $25.8M | $8.2M | $15.6M | $17.4M |
| Total debt | $581,000 | $748,000 | $824,000 | $983,000 | $1.1M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Officer or director change
|
Nov 5, 2026 | Nov 1, 2026 |
| 8-K |
Current report
Other events
|
Oct 26, 2026 | Oct 26, 2026 |
| 8-K |
Current report
Officer or director change
|
Oct 14, 2026 | Oct 7, 2026 |
| 8-K |
Current report
Other events
|
Sep 23, 2026 | Sep 16, 2026 |
| 8-K |
Current report
Other events
|
Sep 14, 2026 | Sep 11, 2026 |
| 8-K |
Current report
Bylaw or fiscal year change, Regulation FD disclosure
|
Aug 24, 2026 | Aug 20, 2026 |
All 532 Longeveron Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.